Illumina: NovaSeq X booming – BioInsight to accelerate growth in 2027
Reading Time: 3 minutes
The stock falls double digits in after-hours trading, despite Illumina raising its forecast – organic growth has slowed down. More than 80 new NovaSeq X devices strengthen recurring revenues, and the clinical business grows by 14% outside of China. BioInsight and Multiomics are expected to deliver additional growth by 2027, while research demand shows initial signals of stabilization. Illumina (ILMN, i) provides devices and consumables for DNA analysis and is building a business with AI data for drug development. Following the figures...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
